Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema (TDMX study)

Phase 2

Completed

• Conditions: Diabetic Macular Oedema; Metabolic and Endocrine - Diabetes; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12605000244606
• Lead Sponsor: Professor Mark Gillies

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-31
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

All patients at the conclusion of the TDMO study. Currently we are still following 64 of the 69 (93%) eyes that were initially entered into the TDMO study that had reduced vision from diabetic macular oedema at baseline.

Exclusion Criteria

Uncontrolled glaucoma; Loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration);known allergies to triamcinolone acetate; patient is already receiving systemic steroid treatment; intercurrent severe disease such as septicemia; any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social, media opacities).

Study & Design

• Study Type: Interventional
• Study Design: Not specified